SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid reported Middle East shipping and energy-infrastructure attacks, fueling concerns about supply disruptions. Traders are divided between expecting the supply-risk rally to continue and anticipating a pullback if tensions ease; some also caution that the expiring WTI contract can distort comparisons with the next contract.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure after HSBC warned that heavy borrowing needs and potentially slower AI-compute demand could challenge its growth and returns, sharpening traders concerns about debt, refinancing, and dilution amid a broader neocloud selloff. Bears warn of credit and business-model risks, while bulls point to contracted demand and continued AI infrastructure growth; some also cite Goldman Sachss more positive view and ARKs share purchases.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares have slid to post-IPO lows amid concern over insider selling and successive lockup share releases, with traders also pointing to a TD Cowen price-target cut and questions about growth, scaling, and reliance on OpenAI. The discussion is sharply divided between calls for more downside and buyers arguing the selloff is overdone and the AI-chip technology has long-term potential.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines and limited firm customer commitments, with uncertainty around the proposed TVA deployment adding to execution concerns. Traders are split between viewing the selloff as an overreaction and seeing it as confirmation of risks facing NuScale and the broader nuclear sector.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound after the recent selloff, ahead of major megacap earnings, is driving QQQ discussion. Traders are divided over whether it marks a durable recovery or a relief rally that could fade, with AI investment and debt concerns and surging oil prices adding to caution.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces third-quarter earnings beat and raised 2026 guidance are driving attention, with traders also citing stronger orders. Many view the report as bullish, while others are cautious about whether the stock can hold its post-earnings strength amid muted or weakening price action.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings and revenue beat estimates, but traders are focused on the tightened full-year profit outlook rather than a larger guidance increase. The new buyback program is a positive offset for some, while others question why shares are falling despite the beat.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrops Q3 results beat expectations and management raised its full-year outlook, with a record backlog reinforcing the growth case. Traders are debating why shares remain under pressure despite the strong report, pointing to margin and cash-flow concerns and the possibility that the positive news was already priced in.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples iPhone Duo preorders reportedly sold out quickly, with deliveries pushed out, drawing bullish attention to demand and the stocks resilience while AI and semiconductor shares faced pressure. Skeptics counter that limited launch supply may explain the sellout and question whether the premium-priced phone will drive meaningful incremental sales, amid broader concerns about Apples valuation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius has been caught in a sharp neocloud and AI-infrastructure selloff as traders debate whether heavy buildout spending can earn adequate returns and whether financing risksespecially at CoreWeavewill spread across the sector. The community is split between treating the rebound after the decline as an oversold bounce and expecting more downside, while some argue Nebius is better positioned than debt-heavier peers and that compute demand remains strong.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years 

Equity

Executive severance changes from June and Sellas’ sizable ASH conference booth have fueled deal speculation.

Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -1.33% move from the previous day.

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

Key PointsRegeneron's leading weight-loss candidate could offer patients an option with fewer side effects...

How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?

LLY's surging Mounjaro and Zepbound sales, alongside Foundayo's expanding market access, strengthen its GLP-1 growth momentum ahead of Q3 results.

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to...

SLS Stock Logs Worst Week In Over A Month: Retail Bulls Bet ASH Embargo Is Keeping Regal Results Under Wraps 

Sellas’s 600-square-foot ASH booth also fueled speculation about a potential clinical update.

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR NewswireINDIANAPOLIS, Oct. 18, 2026 First Phase 1...

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Key PointsEli Lilly could continue to dominate the weight-loss market thanks to medicines like Foundayo and retatrutide...

Lilly’s Foundayo Pill Gets European Regulatory Backing – LLY Stock Heads For Best Week In Nearly Four Months

European Medicines Agency’s advisory committee recommended approval of its once-daily weight-loss pill, Foundayo.


Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?

Key PointsThe sale has nothing to do with the stock's potential, however...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Bullish Sentiment

<ul class="summary-bullets"><li>CEO Angelos Stergiou marked Sellas’ 15th anniversary, pointing to its “next chapter” with GPS and SLS009.</li><li>Retail investors floated $40 billion-$120 billion valuation scenarios and share-price predictions ranging from $100 to $540.&nbsp;</li><li>Investors await Regal’s final-analysis trigger of 80 deaths, following Sellas’ disclosure of 78 events as of May 11.</li></ul>Retail investors in Sellas Life Sciences (SLS) are floating multibillion-dollar buyout scenarios and steep share-price gains after CEO Angelos Stergiou marked the company’s 15th anniversary with a post about its “next chapter.”<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped 5% on Monday to $10.49, snapping three straight losing sessions.&nbsp;<h2 class="st-heading-2">Sellas CEO Points To ‘Best Chapters’ Ahead</h2>In his LinkedIn post, Stergiou reflected on Sellas’ growth from a private startup into a public biotech advancing investigational cancer treatments GPS and SLS009.“Reaching 15 years isn't just about celebrating our history; it is about stepping into our next chapter with even greater focus, drive, and resolve,” he said. He acknowledged past setbacks and thanked shareholders, employees and trial participants, while reaffirming the company’s commitment to patients.“Our mission remains deeply personal, and our promise to the patients we aim to serve is steadfast. We look forward, God willing, to the best chapters that are still to be written with GPS and SLS009,” he added.<h2 class="st-heading-2">SLS Retail Floats Multibillion-Dollar Buyout Scenarios</h2>On Stocktwits, retail sentiment for SLS slipped to ‘bearish’ from ‘bullish’ levels a day ago amid a 258% jump in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_725c1f1d42.png" alt="sls ss.png" width="633" height="343"><figcaption>SLS sentiment and message volume as of October 19 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Reformed_MMAT_investor/message/666881029">said</a>: “My opinion, Dr. Stergiou’s message was a master-class at reassuring EVERYONE that all is well.”A user<a href="https://stocktwits.com/Gebinator/message/666869438"> also&nbsp;floated</a> a minimum $40 billion valuation. Another user<a href="https://stocktwits.com/55X_ROI_Q1_2026/message/666882686">&nbsp;argued</a> for a $50 billion valuation, calling a $247-per-share figure. A separate user<a href="https://stocktwits.com/vlucky16/message/666866929">&nbsp;proposed</a> a $120 billion buyout scenario and also predicted a share price of $540-plus.Across bullish share-price predictions, including scenarios tied to clinical results, targets ranged from $100 to over $540. Discussing buyout news in case of favorable data, one user&nbsp;<a href="https://stocktwits.com/AIALuckyDog/message/666879536">said</a>: “If BO news post good data then there’s no stopping this beast (really no explanation required as it could go full berserker mode).” BO means buyout.Another user challenged the lofty valuations and&nbsp;<a href="https://stocktwits.com/noviceEve/message/666855368">said</a>: “I will be so glad to get out of this ticker when it hits $15 again.”<h2 class="st-heading-2">Retail Searches Filings, Conference Plans For Clues</h2>The CEO’s message comes as investors have been&nbsp;searching for potential deal signals in recent months. In June, a filing disclosed changes to executive severance arrangements, including lump-sum payment provisions for Stergiou.For CFO John Burns and chief development officer Dragan Cicic, qualifying departures within one month before or one year after a change of control would trigger 15 months of salary, the annual target bonus, up to 18 months of health-coverage reimbursements and full vesting of unvested equity.&nbsp;Sellas’ conference plans have provided another talking point. The company is listed at Booth 138, with a 20-by-30-foot space, for the Dec.12- Dec.15 American Society of Hematology (ASH) meeting in New Orleans. Major exhibitors include Eli Lilly, Pfizer, Merck, AbbVie and Bristol Myers Squibb. The booth size has fueled speculation about a partnership or acquisition.<h2 class="st-heading-2">Sellas Regal Trial And SLS009 Data In Focus</h2>Currently, investors are awaiting data from Sellas’ two lead programs. The Phase 3 Regal trial is testing GPS, an immunotherapy targeting WT1, in acute myeloid leukemia (AML) patients who achieved a second complete remission following salvage treatment. Its final-analysis process is triggered by 80 deaths. Sellas reported 78 events as of May 11. Reaching 80 precedes database lock, data review and analysis before results are disclosed.&nbsp;The company also expects fourth-quarter topline data from its 80-patient Phase 2 SLS009 study in newly diagnosed AML, including patients with early resistance to azacitidine and venetoclax. SLS009 is also being explored in pancreatic cancer. Preclinical findings from last month showed 17.9% apoptosis (programmed cell death) in a patient-derived tumor model resistant to Daraxonrasib, versus 2.8% with Daraxonrasib alone. Combining the drugs raised apoptosis to 36.5% and necrosis to 30.6%.&nbsp;SLS stock has surged 178% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avgo-stock-10-year-docomo-deal-retail-on-edge-ceo-ai-casino-remarks/cZxqiudRBuJ">AVGO Stock Edges Up Overnight After 10-Year Docomo Deal, But Retail Stays On Edge Over CEO’s AI ‘Casino’ Remarks&nbsp;</a>

Representative Image (Photo credit: Getty Images)

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years

Abbvie Inc

Bristol-Myers Squibb Co.

Merck & Co Inc

Pfizer Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

$AMD

$SHOP

$UBER

$LLY

$AMD, $SHOP, $UBER, and $LLY are four of the most searched and talked-about stocks among retail investors this morning. Which are you most bullish on? Drop your reasoning in the comments.

Which of these trending stocks are you most bullish on for the next 5 years - $AMD, $SHOP, $UBER, or $LLY? 
 
Explain why in the comments.

Current Price	$1,240.34
Prev Close	$1,257.03
Open	$1,243.39
Dividend Yield	0.56%
50-Day Moving Average	$1,181.44
Beta	0.65
Avg. Volume	2.31M
PE Ratio	42.15

52-Week High	$1,292.65
52-Week Low	$793.82
Market Capitalization	$1.18T
EPS (Annual)	$22.95
Price to Book	34.47
Revenue Per Employee	$1.3M

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

LLY Fundamentals